-transparent.png){kind=logo}
1. Labetalol, a new drug combining alpha-and beta-adrenoceptor blocking properties, has been compared with placebo in a double-blind crossover study of a group of patients with mild to moderate essential hypertension (blood pressure 150/100 to 189/114 mmHg). 2. Labetalol and propranolol lowered blood pressure satisfactorily in the supine position, but labetalol reduced blood pressure more in the erect posture and following exercise and induced less bradycardia. Thus alpha- as well as beta-adrenoceptor blocking actions appear to contribute to blood pressure reduction. 3. Side effects attributable to labetalol were few. The effective dose ratio labetalol: propranolol was 2.5:1 (w/w). 4. Labetalol, a new form of hypotensive agent, merits further controlled assessment of its usefulness in relation to existing drugs.
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
December 1992,
British journal of obstetrics and gynaecology,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
January 1980,
Current medical research and opinion,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
January 1983,
Current medical research and opinion,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
June 1977,
British journal of clinical pharmacology,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
March 1980,
The Medical journal of Australia,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
January 1988,
Journal of cardiovascular pharmacology,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
June 1987,
The Journal of the Association of Physicians of India,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
November 2015,
Seminars in perinatology,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
January 1988,
Journal of cardiovascular pharmacology,
D J Pugsley, and
M Nassim, and
B K Armstrong, and
L Beilin
February 2023,
Journal of the American Academy of Dermatology,
